 The benzoforin-1,3,4-oxidiazole scaffold has been identified as a promising lead structure for the development of novel antitubercular agents. In particular, the benzoforin-1,3-4-oxidiazole derivatives BF3, BF4, and BF8 have shown high potency against the mycobacterium tuberculosis polycotide synthase-13, MTB-PKS-13, enzyme. These compounds also exhibited good stability in the active site of the PKS-13 enzyme, suggesting their potential use as antitubercular drugs. This article was authored by Ali Irfan, Shah Faisal, Amir Fawad Zahor, and others.